Marinomed Biotech AG started trading on the prime market, the top segment of the Vienna Stock Exchange on 1 February 2019. The IPO of Marinomed Biotech AG was the first in Europe this year. The start of trading was traditionally celebrated with the bell-ringing ceremony: The Marinomed management board Andreas Grassauer (CEO), Eva Prieschl-Grassauer (CSO) and Pascal Schmidt (CFO) rang the bell together with Vienna Stock Exchange CEO Christoph Boschan.